within Pharmacolibrary.Drugs.ATC.N;

model N05CB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 60 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.0007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.001,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Combinations of barbiturates (such as phenobarbital with other barbiturates or hypnotics) were historically used as sedative, hypnotic, or anxiolytic agents. They were widely used in the mid-20th century for management of insomnia, anxiety, and certain seizure disorders. Such combinations have generally fallen out of favor and are no longer commonly approved or prescribed today due to safety concerns and risk of overdose.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for combinations of barbiturates (e.g. phenobarbital and amobarbital) are generally not reported for the fixed-dose combinations; parameters are usually available only for single agents. Existing literature does not provide combined PK data. Estimates below are based on the properties of individual oral barbiturates in adults.</p><h4>References</h4><ol><li><p>Rosenfeld, WE, et al., &amp; Nayak, RK (1997). Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. <i>Epilepsia</i> 38(3) 317–323. DOI:<a href=&quot;https://doi.org/10.1111/j.1528-1157.1997.tb01123.x&quot;>10.1111/j.1528-1157.1997.tb01123.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9070594/&quot;>https://pubmed.ncbi.nlm.nih.gov/9070594</a></p></li><li><p>Hvidberg, EF, &amp; Dam, M (1976). Clinical pharmacokinetics of anticonvulsants. <i>Clinical pharmacokinetics</i> 1(3) 161–188. DOI:<a href=&quot;https://doi.org/10.2165/00003088-197601030-00001&quot;>10.2165/00003088-197601030-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/797496/&quot;>https://pubmed.ncbi.nlm.nih.gov/797496</a></p></li><li><p>Ohtani, H, et al., &amp; Akiyoshi, T (2016). In silico evaluation of warfarin-bucolome therapy. <i>Biopharmaceutics &amp; drug disposition</i> 37(4) 233–242. DOI:<a href=&quot;https://doi.org/10.1002/bdd.2008&quot;>10.1002/bdd.2008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27214159/&quot;>https://pubmed.ncbi.nlm.nih.gov/27214159</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05CB01;
